These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9138100)

  • 21. Hypocalcemic effect of salmon calcitonin following single and repeated nasal and intravenous administration in young rabbits.
    Schipper NG; Romeijn SG; Verhoef J; Merkus FW
    Calcif Tissue Int; 1994 Jan; 54(1):50-5. PubMed ID: 8118754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of rectal and nasal administration of salmon calcitonin in normal subjects.
    Buclin T; Randin JP; Jacquet AF; Azria M; Attinger M; Gomez F; Burckhardt P
    Calcif Tissue Int; 1987 Nov; 41(5):252-8. PubMed ID: 3121149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis.
    Thamsborg G; Jensen JE; Kollerup G; Hauge EM; Melsen F; Sorensen OH
    Bone; 1996 Feb; 18(2):207-12. PubMed ID: 8833216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Centrally and peripherally induced anorectic actions of salmon calcitonin (sCT) in rats: separation of its novel derivative [Gly8]-sCT].
    Nakamuta H; Koida M; Ogawa Y; Orlowski RC
    Nihon Yakurigaku Zasshi; 1987 Apr; 89(4):191-5. PubMed ID: 3038715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison with hydroxypropyl- and dimethyl-beta-cyclodextrins.
    Sinswat P; Tengamnuay P
    Int J Pharm; 2003 May; 257(1-2):15-22. PubMed ID: 12711157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methylated beta-cyclodextrins are able to improve the nasal absorption of salmon calcitonin.
    Schipper NG; Verhoef JC; Romeijn SG; Merkus FW
    Calcif Tissue Int; 1995 Apr; 56(4):280-2. PubMed ID: 7767838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversible lipidization for the oral delivery of salmon calcitonin.
    Wang J; Chow D; Heiati H; Shen WC
    J Control Release; 2003 Mar; 88(3):369-80. PubMed ID: 12644363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of HPβCD-PEG microparticles for salmon calcitonin administration via pulmonary delivery.
    Tewes F; Gobbo OL; Amaro MI; Tajber L; Corrigan OI; Ehrhardt C; Healy AM
    Mol Pharm; 2011 Oct; 8(5):1887-98. PubMed ID: 21882837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent nasal salmon calcitonin therapy.
    Peichl P; Rintelen B; Kumpan W; Bröll H
    Gynecol Endocrinol; 1999 Feb; 13(1):7-14. PubMed ID: 10368793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral multiple w/o/w emulsion formulation of a peptide salmon calcitonin: in vitro-in vivo evaluation.
    Dogru ST; Calis S; Oner F
    J Clin Pharm Ther; 2000 Dec; 25(6):435-43. PubMed ID: 11123497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis.
    Bandeira L; Lewiecki EM; Bilezikian JP
    Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):681-9. PubMed ID: 27070719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of Paget's disease of bone with a combination of intranasal salmon calcitonin and oral calcium and thiazide.
    Evans RA; Somers NM; Dunstan CR; Hills E; Evans M
    Calcif Tissue Int; 1991 Sep; 49(3):164-7. PubMed ID: 1933580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prominent circadian absorption of intranasal salmon calcitonin (SCT) in healthy subjects.
    Tarquini B; Cavallini V; Cariddi A; Checchi M; Sorice V; Cecchettin M
    Chronobiol Int; 1988; 5(2):149-52. PubMed ID: 3401980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats.
    Ahsan F; Arnold J; Meezan E; Pillion DJ
    Pharm Res; 2001 Dec; 18(12):1742-6. PubMed ID: 11785695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection.
    Youn YS; Kwon MJ; Na DH; Chae SY; Lee S; Lee KC
    J Control Release; 2008 Jan; 125(1):68-75. PubMed ID: 18023905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thermosensitive drug delivery system of salmon calcitonin: in vitro release, in vivo absorption, bioactivity and therapeutic efficacies.
    Tang Y; Singh J
    Pharm Res; 2010 Feb; 27(2):272-84. PubMed ID: 19998055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of osteoporosis with nasal salmon calcitonin: effect of anti-salmon calcitonin antibody formation.
    Reginster JY; Gaspar S; Deroisy R; Zegels B; Franchimont P
    Osteoporos Int; 1993 Sep; 3(5):261-4. PubMed ID: 8400608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two-site immunofluorometric assay of intact salmon calcitonin with improved sensitivity.
    Rong H; Deftos LJ; Ji H; Bucht E
    Clin Chem; 1997 Jan; 43(1):71-5. PubMed ID: 8990225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucocorticoid-induced secondary osteopenia in female rats: a time course study as compared with ovariectomy-induced osteopenia and response to salmon calcitonin.
    Nitta T; Fukushima T; Nakamuta H; Koida M
    Jpn J Pharmacol; 1999 Mar; 79(3):379-86. PubMed ID: 10230867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stability of PEGylated salmon calcitonin in nasal mucosa.
    Na DH; Youn YS; Park EJ; Lee JM; Cho OR; Lee KR; Lee SD; Yoo SD; DeLuca PP; Lee KC
    J Pharm Sci; 2004 Feb; 93(2):256-61. PubMed ID: 14705183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.